Registration - In-house Corporation

Subject Matters

• Budget
• Health
• Industry
• Intellectual Property
• International Development
• International Trade
• Justice and Law Enforcement
• Privacy and Access to Information
• Research and Development
• Science and Technology

Subject Matter Details

Legislative Proposal, Bill or Resolution

• Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
• Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.

Legislative Proposal, Bill or Resolution, Policies or Program

• The House of Commons Standing Committee on Health's (HESA) and the Standing Committee on Social Affairs review of the 2004-2014 Health Accord and renegotiation of the 2014 Health Accord

Legislative Proposal, Bill or Resolution, Policies or Program, Regulation

• Research and Development: Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D

Policies or Program

• Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
• Input into the Patented Medicines Price Review Board evaluation of annual Research and Development investments by companies in Canada based on SR&ED tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.

Policies or Program, Regulation

• Health Canada PMPRB proposed regulation changes are the regulatiuons Health Canada consulted on Proposed Amendments to the Patented Medicines Regulations. Discussions on changing the basket of comparative countries and its unintended economic consequences in Canada. In particular its impact on the Life Sciences Sector and wait times for medicines for Canadians Title: “Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations”

Regulation

• An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
• Health Canada's proposal to add the drug tramadol to the Schedule of the Narcotic Control Regulations (NCR) with regard to changing the status of this prescription product to a controlled substance and the scheduling process for new products
• Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (EMA/FDA).
• Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.

Communication Techniques

• Written communication
• Oral communication

Government Institutions

• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Senate of Canada

Address:
19 Green Belt Drive
Toronto, ON  M3C 1L9
Canada

Telephone number: 416-449-9444
Fax number: 416-449-2658  

Parent Company Information